Table 1 Base-case cost-effectiveness results from a decision tree and Markov model
|  | Infliximab | Ciclosporin | Difference (ciclos – inflx) | Cost-effectiveness | |||
|---|---|---|---|---|---|---|---|
Costs (£) | QALYs | Costs (£) | QALYs | Costs (£) | QALYs |  | |
Decision tree (2-year) | 18,608 | 1.561 | 11,705 | 1.596 | -6,902 | 0.035 | Ciclosporin dominates |
Markov model (beyond 2-year trial FU and over 18Â years) | 15,748 | 7.613 | 15,103 | 8.219 | -645 | 0.606 | Ciclosporin dominates |
Base-case (20-yr time horizon); DT + MM | 34,185 | 9.106 | 26,793 | 9.816 | -7,392 | 0.710 | Ciclosporin dominates |